PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

From OCR and ECAR to energy: perspectives on the design and interpretation of bioenergetics studies

(2021) Cameron A. Schmidt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation

(2020) Luis Eduardo Alves Damasceno et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors

(2020) Yuan Wei et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice

(2019) Yuan Wei et al.   GASTROENTEROLOGY

Glycolytic Activation of Peritumoral Monocytes Fosters Immune Privilege via PFKFB3-PD-L1 axis in Human Hepatocellular Carcinoma

(2019) Dong-Ping Chen et al.   JOURNAL OF HEPATOLOGY

Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT

(2019) Bifei Li et al.   OncoTargets and Therapy

Macrophages and Metabolism in the Tumor Microenvironment

(2019) Ilio Vitale et al.   Cell Metabolism

The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy

(2019) Yuan Wei et al.   JOURNAL OF CLINICAL INVESTIGATION

M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling

(2019) Zhaoyun Zong et al.   Frontiers in Immunology

Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells

(2018) Xiaoqing Zhang et al.   Cellular & Molecular Immunology

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

(2018) Ganjun Yu et al.   Cellular & Molecular Immunology

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

(2018) Xiaolei Li et al.   Cellular & Molecular Immunology

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy

(2018) Jia Long et al.   Cancer Biology & Medicine

Diverse Functions of Macrophages in Different Tumor Microenvironments

(2018) Ming Yang et al.   CANCER RESEARCH

Fatty Acid Oxidation in Macrophages and T Cells: Time for Reassessment?

(2018) Jan Van den Bossche et al.   Cell Metabolism

Macrophage Immunometabolism: Where Are We (Going)?

(2017) Jan Van den Bossche et al.   TRENDS IN IMMUNOLOGY

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

(2016) Julie George et al.   CLINICAL CANCER RESEARCH

The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease

(2016) Tsuyoshi Shirai et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization

(2016) M.-M. Chen et al.   Cancer Discovery

Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4

(2015) P. Prakash et al.   BLOOD

Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages

(2015) Eva M. Palsson-McDermott et al.   Cell Metabolism

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunometabolism governs dendritic cell and macrophage function

(2015) Luke A.J. O’Neill et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine

(2015) Ziad Julier et al.   Scientific Reports

Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer

(2013) Young Kyung Bae et al.   HUMAN PATHOLOGY

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

Oligomycin frames a common drug-binding site in the ATP synthase

(2012) J. Symersky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer

(2010) Sandra Waalkes et al.   BMC CANCER

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology